{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:03:37Z","timestamp":1761555817154,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["N01-CM-2011-00038","NO1 CM-62209","P30CA033572","UM1CA186717"],"award-info":[{"award-number":["N01-CM-2011-00038","NO1 CM-62209","P30CA033572","UM1CA186717"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cct.2023.107083","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T02:23:07Z","timestamp":1673317387000},"page":"107083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data"],"prefix":"10.1016","volume":"125","author":[{"given":"Carolyn E.","family":"Behrendt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2023.107083_bb0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2141.2005.05923.x","article-title":"Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation","volume":"132","author":"Artz","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cct.2023.107083_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100583","article-title":"Untenable dosing: a common pitfall of modern DLT-targeting phase I designs in oncology","volume":"44","author":"Frankel","year":"2020","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.cct.2023.107083_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2023.107083_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J. R. Stat. Soc. Ser. A"},{"key":"10.1016\/j.cct.2023.107083_bb0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jrsm.1384","article-title":"Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example","volume":"11","author":"DeJong","year":"2020","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.cct.2023.107083_bb0030","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/sim.7171","article-title":"One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across trial information","volume":"36","author":"Hua","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2023.107083_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cct.2023.107083_bb0045","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/JTO.0b013e318225924c","article-title":"Bortezomib for patients with advanced stage bronchioloalveolar carcinoma (BAC): a California Cancer consortium phase II study (NCI #7003)","volume":"6","author":"Ramalingam","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0050","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s10637-020-01038-6","article-title":"Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored California Cancer consortium trial, NCI 6879","volume":"39","author":"Quinn","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.cct.2023.107083_bb0055","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0060","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","article-title":"A phase II study of belinostat (PXD101) in patients with relapsed or refractory acute myloid leukemia or patients over 60 with newly-diagnosed acute myloid leukemia: a California Cancer consortium study","volume":"55","author":"Kirschbaum","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cct.2023.107083_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CLC.2011.n.004","article-title":"Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial","volume":"12","author":"Lara","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.cct.2023.107083_bb0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.14333","article-title":"A phase II study of VEGF trap (aflibercept, NSC 724770) in patients with MDS: a California Cancer consortium study","volume":"180","author":"Kirschbaum","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cct.2023.107083_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JTO.0b013e31823f43ca","article-title":"A phase II study of halichondrin B analogue eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California Cancer consortium trial","volume":"7","author":"Gitlitz","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0080","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.urology.2010.04.025","article-title":"Phase II study of aflibercept (VEGF-trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer consortium trial","volume":"76","author":"Twardowski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.cct.2023.107083_bb0085","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-11-1463","article-title":"Aflibercept (VEGF trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin","volume":"17","author":"Tarhini","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2023.107083_bb0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non\u2013small-cell lung cancer","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0100","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/bjc.2015.126","article-title":"A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas","volume":"112","author":"Eroglu","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cct.2023.107083_bb0105","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer consortium trial NCT01149083","volume":"23","author":"Somlo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2023.107083_bb0115","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.31734","article-title":"NCI 8628 - a randomized phase II study of ziv-aflibercept and high dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma","volume":"124","author":"Tarhini","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.cct.2023.107083_bb0120","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1158\/1078-0432.CCR-14-3281","article-title":"Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non\u2013small cell lung cancer who previously progressed on erlotinib","volume":"21","author":"Lara","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cct.2023.107083_bb0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/KCA-180041","volume":"3","author":"Semrad","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.cct.2023.107083_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fonc.2019.00132","volume":"9","author":"Reckamp","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0135","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.19.00861","article-title":"Phase II California Cancer consortium trial of gemcitabine-eribulin combination in cisplatin-ineligible patients with metastatic urothelial carcinoma: final report (NCI-9653)","volume":"27","author":"Sadeghi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0140","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: a phase II randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cct.2023.107083_bb0145","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.3390\/cancers13102304","article-title":"Clinical predictors of early trial discontinuation for patients participating in phase I clinical trials in oncology","volume":"13","author":"Douma","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cct.2023.107083_bb0150","doi-asserted-by":"crossref","first-page":"19316","DOI":"10.18632\/oncotarget.2909","article-title":"Predictors of early treatment discontinuation in patients enrolled on phase I oncology trials","volume":"6","author":"Hyman","year":"2015","journal-title":"Oncotarget"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442300006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442300006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:58:08Z","timestamp":1761555488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171442300006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"alternative-id":["S155171442300006X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107083","relation":{},"ISSN":["1551-7144"],"issn-type":[{"type":"print","value":"1551-7144"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107083"}}